1887

Abstract

To evaluate the antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 nonduplicate isolates (23.7 % isolated from HAP, 46.8 % from SSTI and 29.5 % from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant , 867 methicillin-sensitive , 299 coagulase-negative (CoNS), 104 , 99 , 13 , 23 α-haemolytic and 103 β-haemolytic . MICs of routine clinical antibiotics were determined by broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines 2015. Tedizolid, linezolid, vancomycin, daptomycin, teicoplanin and tigecycline showed high activity against Gram-positive pathogens (≥98.0 % susceptible), and tedizolid exhibited four- to eight fold greater activity than linezolid against the pathogens tested, with MICs of methicillin-resistant , α-haemolytic and β-haemolytic (0.25 vs 2 µg ml); methicillin-sensitive , and (0.5 vs 2 µg ml); methicillin-resistant CoNS and methicillin-sensitive CoNS (0.25 vs 1 µg ml); and (0.125 vs 0.5 µg ml). Tedizolid MICs associated with different infections did not show significant differences, and the drug exhibited excellent activity against surveyed Gram-positive pathogens associated with HAP, SSTI and BSI, including linezolid-nonsusceptible strains. These data suggest that tedizolid could be an alternative to linezolid for the treatment of infections caused by Gram-positive organisms.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000347
2016-10-18
2020-09-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/10/1215.html?itemId=/content/journal/jmm/10.1099/jmm.0.000347&mimeType=html&fmt=ahah

References

  1. Burdette S. D., Trotman R.. 2015; Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis61:1315–1321 [CrossRef][PubMed]
    [Google Scholar]
  2. CLSI 2015; Performance Standards for Antimicrobial Susceptibility Testing; 25th Informational Supplement. Approved Standard M07-A10 , 10th edn. Wayne, PA: Clinical and Laboratory Standard Institute;
    [Google Scholar]
  3. Das D., Tulkens P. M., Mehra P., Fang E., Prokocimer P.. 2014; Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis58:S51–S57 [CrossRef][PubMed]
    [Google Scholar]
  4. Douros A., Grabowski K., Stahlmann R.. 2015; Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol11:1849–1859 [CrossRef][PubMed]
    [Google Scholar]
  5. FDA 2014; Center for drug evaluation and research. application number: 205435Orig1s000 Microbiology / Virology review(S). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MicroR.pdf
  6. Guo Y., Wang H., Zhao C., Wang Z., Zhang F., Cao B., Hu B., Liao K., Mei Y. et al. 2012; Antimicrobial resistance surveillance of gram-positive cocci isolated from 14 hospitals in China in 2011. Chin J Lab Med35:1021–2028 (in Chinese)
    [Google Scholar]
  7. Guo Y., Wang H., Zhao C., Wang Z., Cao B., Xu Y., Hu B., Ni Y., Zhang L. et al. 2013; A surveillance study of antimicrobial resistance of gram-positive cocci strains isolated from 16 teaching hospitals in China in 2012. Chin J Microbiol Immunol33:401–409 (in Chinese)
    [Google Scholar]
  8. Guo Y., Wang H., Zhao C., Zhang F., Wang Z., Cao B., Xu Y., Chen M., Hu B. et al. 2015; Antimicrobial resistance surveillance of gram-positive cocci isolated from 15 teaching hospitals in China in 2013. Chin J Lab Med38:1–10 (in Chinese)
    [Google Scholar]
  9. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F. C.. 1997; Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother40:135–136 [CrossRef][PubMed]
    [Google Scholar]
  10. Kanafani Z. A., Corey G. R.. 2012; Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 21:515–522 [CrossRef]
    [Google Scholar]
  11. Kisgen J. J., Mansour H., Unger N. R., Childs L. M.. 2014; Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm71:621–633 [CrossRef][PubMed]
    [Google Scholar]
  12. Leclercq R., Derlot E., Duval J., Courvalin P.. 1988; Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med319:157–161 [CrossRef][PubMed]
    [Google Scholar]
  13. Moellering R. C.. 2003; Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med138:135–142 [CrossRef][PubMed]
    [Google Scholar]
  14. Moran G. J., Fang E., Corey G. R., Das A. F., De Anda C., Prokocimer P.. 2014; Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis14:696–705 [CrossRef][PubMed]
    [Google Scholar]
  15. Prokocimer P., Bien P., Surber J., Mehra P., DeAnda C., Bulitta J. B., Corey G. R.. 2011; Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother55:583–592 [CrossRef][PubMed]
    [Google Scholar]
  16. Prokocimer P., De Anda C., Fang E., Mehra P., Das A.. 2013; Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA309:559–569 [CrossRef][PubMed]
    [Google Scholar]
  17. Rice L. B.. 2006; Antimicrobial resistance in gram-positive bacteria. Am J Med119:S11–19 [CrossRef][PubMed]
    [Google Scholar]
  18. Sahm D. F., Deane J., Bien P. A., Locke J. B., Zuill D. E., Shaw K. J., Bartizal K. F.. 2015; Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis81:112–118 [CrossRef][PubMed]
    [Google Scholar]
  19. Shaw K. J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C. M., Shinabarger D., Zurenko G.. 2008; In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother52:4442–4447 [CrossRef][PubMed]
    [Google Scholar]
  20. Sievert D. M., Ricks P., Edwards J. R., Schneider A., Patel J., Srinivasan A., Kallen A., Limbago B., Fridkin S.. National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities 2013; Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol34:1–14 [CrossRef][PubMed]
    [Google Scholar]
  21. Stryjewski M. E., Corey G. R.. 2014; Methicillin-resistant Staphylococcus aureus: an evolving pathogen. Clin Infect Dis58:S10–S19 [CrossRef][PubMed]
    [Google Scholar]
  22. Tsai H. Y., Liao C. H., Chen Y. H., Lu P. L., Huang C. H., Lu C. T., Chuang Y. C., Tsao S. M., Chen Y. S. et al. 2012; Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline in vitro surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob Agents Chemother56:3402–3405 [CrossRef][PubMed]
    [Google Scholar]
  23. Winston L. G., Perlman J. L., Rose D. A., Gerberding J. L.. 1999; Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis29:580–585[PubMed][CrossRef]
    [Google Scholar]
  24. Woodford N., Livermore D. M.. 2009; Infections caused by gram- positive bacteria: a review of the global challenge. J Infect59:S4–16 [CrossRef][PubMed]
    [Google Scholar]
  25. Zhanel G. G., Love R., Adam H., Golden A., Zelenitsky S., Schweizer F., Gorityala B., Lagacé-Wiens P. R., Rubinstein E. et al. 2015; Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs75:253–270 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000347
Loading
/content/journal/jmm/10.1099/jmm.0.000347
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error